# PMGC Holdings Inc. (ELAB) — divestiture/joint_venture [announced]
Source: SEC API (secapi.ai) · situation sit_c7cd787b548eb6c3ff64 · retrieved 2026-08-11T15:49:18.364Z

## Overview
PMGC Holdings Inc. is a pharmaceutical company that operates through subsidiaries including NorthStrive Defense Tech LLC, which develops aerospace and defense technologies.

On June 30, 2026, NorthStrive Defense Tech LLC, a wholly owned subsidiary of PMGC Holdings Inc., entered into a Standard Exclusive License Agreement with a licensor to obtain a worldwide, non-transferable, exclusive license to make, use, sell, and import licensed products covered by U.S. Patent No. 12,291,334 and associated know-how in the aerospace and defense technologies field. NorthStrive Defense Tech has the right to grant sublicenses to third parties subject to the agreement's terms. The licensee must achieve specified diligence milestones and provide annual development reports. Financial consideration includes a non-refundable license issue fee due within 30 days, annual license maintenance fees commencing on the first anniversary until first net sales are achieved, royalties on net sales, and sublicense payments to the licensor.

## Terms
- Counterparty: Licensor (undisclosed) · Consideration: mixed

## Key dates
- Announced 2026-07-07 · Expected close 2026-06-30

## Timeline
- 2026-07-07 · 8-K (0001213900-26-076053): 8-K - PMGC Holdings Inc. — *PMGC Holdings Inc. is a pharmaceutical company that operates through subsidiaries including NorthStrive Defense Tech LLC, which develops aerospace and defense technologies.* On June 30, 2026, NorthStrive Defense Tech LLC, a wholly owned subsidiary of PMGC Holdings Inc., entered into a Standard Exclusive License Agreement with a licensor to obtain a worldwide, non-transferable, exclusive license to make, use, sell, and import licensed products covered by U.S. Patent No. 12,291,334 and associated know-how in the aerospace and defense technologies field. NorthStrive Defense Tech has the right to grant sublicenses to third parties subject to the agreement's terms. The licensee must achieve specified diligence milestones and provide annual development reports. Financial consideration includes a non-refundable license issue fee due within 30 days, annual license maintenance fees commencing on the first anniversary until first net sales are achieved, royalties on net sales, and sublicense payments to the licensor.
  https://www.sec.gov/Archives/edgar/data/1840563/0001213900-26-076053.txt

## Citations
- 0001213900-26-076053 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000121390026076053